Suppr超能文献

草药产品的药物安全性方面

Drug safety aspects of herbal medicinal products.

作者信息

Wegener T, Deitelhoff B, Silber-Mankowsky A

机构信息

Consulting HMP, Brückstraße 11, 69469, Weinheim, Germany,

出版信息

Wien Med Wochenschr. 2015 Jun;165(11-12):243-50. doi: 10.1007/s10354-015-0370-9. Epub 2015 Jul 17.

Abstract

There are numerous statements in the literature suggesting that the safety of herbal products or herbal medicinal products is inadequately considered. Despite the presence of risk, the potential is commonly underestimated as herbals are considered to be natural substances. It is necessary to consider the different categories of herbal products in the market. On one hand there are authorised herbal medicinal products (HMPs) which have adhered to the requirements to present data on quality, efficacy and safety. On the other hand there are products falling outside the use of marketing authorisations as for remedies. In the European Union (EU), HMPs are subject to an ambitious and comprehensive risk management system as for chemically defined drugs, which react effectively to risk concerns with scientific methods, as has been shown in the past. The established methods of pharmacovigilance and risk management favour the authorisation of herbal preparations for medicinal purposes as proprietary medicinal drugs.

摘要

文献中有众多陈述表明,草药产品或草药药品的安全性未得到充分考量。尽管存在风险,但由于草药被视为天然物质,其潜力通常被低估。有必要考虑市场上不同类别的草药产品。一方面是已获授权的草药药品,它们符合提供质量、疗效和安全性数据的要求。另一方面是不属于药品销售授权范围的产品,如补救措施。在欧盟,草药药品如同化学合成药物一样,要接受一套雄心勃勃且全面的风险管理体系,过去已表明该体系能以科学方法有效应对风险问题。既定的药物警戒和风险管理方法有利于将用于医疗目的的草药制剂批准为专利药品。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验